Is AstraZeneca PLC (AZN) a good stock to buy?

Olyth's institutional analysis of AZN reveals an Altman Z-Score of 2.49 and a Piotroski F-Score of 7/9. These metrics, combined with its 5-year revenue trend ($58.74B most recent), help investors decide if AZN fits their risk profile.

What is the current P/E ratio for AZN?

As of the latest trading session, AstraZeneca PLC (AZN) has a trailing P/E ratio of 30.24.

Who is the CEO of AstraZeneca PLC?

The current Chief Executive Officer of AstraZeneca PLC is Pascal Claude Roland Soriot.

What was AZN's revenue for the last 5 years?

According to its latest income statements, AstraZeneca PLC reported annual revenues of $58.74B (2025), $54.07B (2024), $45.81B (2023), $44.35B (2022), $37.42B (2021) respectively.

Does AZN pay a dividend?

AstraZeneca PLC currently pays a dividend to its shareholders, with a trailing dividend yield of 1.54%.

How much debt and cash flow does AZN have?

In its latest reporting period, AstraZeneca PLC generated $11.77B in Free Cash Flow against a total debt load of $29.70B.

What is the Price-to-Book (P/B) ratio of AstraZeneca PLC?

The Price-to-Book (P/B) ratio for AstraZeneca PLC (AZN) is currently 6.44.

What is the Price-to-Sales (P/S) ratio of AZN?

Based on trailing twelve-month data, AstraZeneca PLC (AZN) trades at a Price-to-Sales (P/S) ratio of 5.27.

What is AstraZeneca PLC's Return on Equity (ROE)?

AstraZeneca PLC (AZN) has a Return on Equity (ROE) of 23.00%, representing its profitability relative to shareholder equity.

AZN

AstraZeneca PLC · Healthcare

203.49

1.37%(+2.76)

Market Closed

204.50

0.50%(+1.01)

After Hours

Last Updated: — ET

52W L: $122.4852W H: $212.71

$204.49

CHG-187.85 (-47.88%)

H$403.06

L$178.81

VOL26M

AZN (1h)

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

94,300

IPO Date

1993-05-12

Beta

0.28

Websitewww.astrazeneca.com↗

AZN

AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns

Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Global pharma companies that have publicly announced Trump drug pricing agreements

Here Are Thursday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Astra-Zeneca, Brinker, e.l.f. Beauty, Freeport-McMoran, Vale, Wingstop, Wix.com, and More

AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial